Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome

Cristina Woellner, E. Michael Gertz, Alejandro A. Schäffer, Macarena Lagos, Mario Perro, Erik Oliver Glocker, Maria C. Pietrogrande, Fausto Cossu, José L. Franco, Nuria Matamoros, Barbara Pietrucha, Edyta Heropolitańska-Pliszka, Mehdi Yeganeh, Mostafa Moin, Teresa Español, Stephan Ehl, Andrew R. Gennery, Mario Abinun, Anna Breborowicz, Tim NiehuesSara Sebnem Kilic, Anne Junker, Stuart E. Turvey, Alessandro Plebani, Berta Sánchez, Ben Zion Garty, Claudio Pignata, Caterina Cancrini, Jiri Litzman, Özden Sanal, Ulrich Baumann, Rosa Bacchetta, Amy P. Hsu, Joie N. Davis, Lennart Hammarström, E. Graham Davies, Efrem Eren, Peter D. Arkwright, Jukka S. Moilanen, Dorothee Viemann, Sujoy Khan, László Maródi, Andrew J. Cant, Alexandra F. Freeman, Jennifer M. Puck, Steven M. Holland, Bodo Grimbacher

    Research output: Contribution to journalArticlepeer-review


    Background: The hyper-IgE syndrome (HIES) is a primary immunodeficiency characterized by infections of the lung and skin, elevated serum IgE, and involvement of the soft and bony tissues. Recently, HIES has been associated with heterozygous dominant-negative mutations in the signal transducer and activator of transcription 3 (STAT3) and severe reductions of TH17 cells. Objective: To determine whether there is a correlation between the genotype and the phenotype of patients with HIES and to establish diagnostic criteria to distinguish between STAT3 mutated and STAT3 wild-type patients. Methods: We collected clinical data, determined TH17 cell numbers, and sequenced STAT3 in 100 patients with a strong clinical suspicion of HIES and serum IgE >1000 IU/mL. We explored diagnostic criteria by using a machine-learning approach to identify which features best predict a STAT3 mutation. Results: In 64 patients, we identified 31 different STAT3 mutations, 18 of which were novel. These included mutations at splice sites and outside the previously implicated DNA-binding and Src homology 2 domains. A combination of 5 clinical features predicted STAT3 mutations with 85% accuracy. TH17 cells were profoundly reduced in patients harboring STAT3 mutations, whereas 10 of 13 patients without mutations had low (1000IU/mL plus a weighted score of clinical features >30 based on recurrent pneumonia, newborn rash, pathologic bone fractures, characteristic face, and high palate. Probable: These characteristics plus lack of TH17 cells or a family history for definitive HIES. Definitive: These characteristics plus a dominant-negative heterozygous mutation in STAT3. © 2010 American Academy of Allergy, Asthma & Immunology.
    Original languageEnglish
    Pages (from-to)424-e8
    JournalJournal of Allergy and Clinical Immunology
    Issue number2
    Publication statusPublished - Feb 2010


    Dive into the research topics of 'Mutations in STAT3 and diagnostic guidelines for hyper-IgE syndrome'. Together they form a unique fingerprint.

    Cite this